Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FKFV3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,763
Award facts
- Contract value 100% obligated
- $16,762.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,762.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on January 26, 2026, for the supply of Nexplanon 68 mg implants, a subdermal contraceptive device. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform the work at its Park Ridge facility. This delivery order was issued without a set-aside designation, indicating the award was made through open competition. The contract has an ultimate completion date of February 17, 2026.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. That parent contract, valued at $499.9 million and awarded November 13, 2025, positions DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy designed to supply pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally. The parent contract structure includes a 30-month base period with three 30-month option periods extending through December 31, 2036, enabling DLA to issue firm fixed-price delivery orders for diverse pharmaceutical requirements across military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FKFV3?
SPE2DR26FKFV3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 26, 2026.
How much is contract SPE2DR26FKFV3 worth?
The government has obligated $16,763 on SPE2DR26FKFV3.
Is contract SPE2DR26FKFV3 an order under another contract?
Yes. SPE2DR26FKFV3 is a delivery order under SPE2DR25D9362, an indefinite delivery contract.
Was contract SPE2DR26FKFV3 competed?
The extent of competition for SPE2DR26FKFV3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award